Adjunctive use of VTAMA (tapinarof) 1% cream in the management of new-onset scalp psoriasis in a patient with fistulizing Crohn's disease on infliximab

Kyle T. Machynia

doi:10.18203/issn.2455-4529.IntJResDermatol20250020

Authors

Kyle T. Machynia University of Nevada, Reno School of Medicine. Reno, NV, USA

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20250020

Keywords:

Psoriasis, Crohn’s disease, VTAMA (tapinarof) 1% cream, Inflammatory bowel disease, Infliximab

Abstract

Psoriasis (PsO) frequently coexists with inflammatory bowel disease (IBD), including Crohn's disease (CD). Patients with CD on tumor necrosis factor (TNF)-alpha inhibitors, such as infliximab (IFX), are at an increased risk for developing PsO. The paradoxical development of PsO in this patient population presents a therapeutic challenge, particularly in those with fistulizing CD, as switching to IL-23 inhibitors is not a viable option due to their reduced efficacy in promoting fistula healing. Effective treatment strategies that can manage PsO without compromising CD control are therefore necessary. Here we report a case of new onset scalp PsO treated with tapinarof 1% cream with significant improvement noted after 2 weeks of application and maintains clearance of scalp PsO with biweekly application.

Metrics

Metrics Loading ...

References

Cottone M, Sapienza C, Macaluso FS, Cannizzaro M. Psoriasis and Inflammatory Bowel Disease. Digest Dis (Basel). 2019;37(6):451-7. DOI: https://doi.org/10.1159/000500116

Tabbarah S, Sulaiman H, Ansah OF, Rajeev JM, Marepalli NR, Pino N, et al. Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection. Cureus. 2024;16(9):e70148. DOI: https://doi.org/10.7759/cureus.70148

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012;107(9):1409-22. DOI: https://doi.org/10.1038/ajg.2012.218

Fréling E, Baumann C, Cuny J, Bigard M, Schmutz J, Barbaud A, et al. Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience. Am J Gastroenterol. 2015;110(8):1186-96. DOI: https://doi.org/10.1038/ajg.2015.205

Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. J Crohns Colitis. 2020;14(3):351-60. DOI: https://doi.org/10.1093/ecco-jcc/jjz152

Fu Y, Lee C, Chi C. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018;154(12):1417-23.

Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis. 2013;72(7):1200-5. DOI: https://doi.org/10.1136/annrheumdis-2012-202143

Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2:e000239. DOI: https://doi.org/10.1136/rmdopen-2015-000239

Steinwurz F, Denadai R, Saad-Hossne R, Queiroz ML, Teixeira FV, Romiti R. Infliximab-induced psoriasis during therapy for Crohn's disease. J Crohn's Colitis. 2012;6(5):610-6. DOI: https://doi.org/10.1016/j.crohns.2011.12.007

Mohammed RHA, Essam M, Anwar I, Shehab H, Komy ME. Psoriasis paradox-infliximab-induced psoriasis in a patient with Crohn's disease: a case report and mini-review. J Int Med Res. 2023;51(9):3000605231200270. DOI: https://doi.org/10.1177/03000605231200270

Manni E, Barachini P. Psoriasis induced by infliximab in a patient suffering from Crohn's disease. Int J Immunopathol Pharmacol. 2009;22(3):841-4. DOI: https://doi.org/10.1177/039463200902200331

Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. J Psoriasis Psoriatic Arthritis. 2019;4(2):70-80. DOI: https://doi.org/10.1177/2475530318810851

Cleynen, I, Vermeire, S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496-503. DOI: https://doi.org/10.1038/nrgastro.2012.125

Townsend CM, Nguyen TM, Cepek J, Abbass M, Parker CE, MacDonald JK, et al. Adalimumab for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2020;5(5):CD012877. DOI: https://doi.org/10.1002/14651858.CD012877.pub2

Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9):876-85. DOI: https://doi.org/10.1056/NEJMoa030815

Wetwittayakhlang P, Al Khoury A, Hahn GD, Lakatos PL. The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials. J Clin Med. 2022;11(11):3045. DOI: https://doi.org/10.3390/jcm11113045

Panaccione R, Colombel JF, Sandborn WJ. Long-term infliximab treatment for Crohn's disease: Analysis of remission, fistula healing, and hospitalizations in the ACCENT I study. Am J Gastroenterol. 2013;108(3):389-96.

Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S. Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials. J Dermatol. 2024;51(10):1269-78. DOI: https://doi.org/10.1111/1346-8138.17423

Bagel J, Gold LS, Rosso JD, Johnson S, Yamauchi P, Brown PM, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial. J American Acad Dermatol. 2023;89(5):936-44. DOI: https://doi.org/10.1016/j.jaad.2023.04.061

Fiorino G, Omodei PD. Psoriasis and Inflammatory Bowel Disease: Two Sides of the Same Coin? J Crohn's Colitis. 2015;9(9):697-8. DOI: https://doi.org/10.1093/ecco-jcc/jjv110

Fu Y, Lee C, Chi C. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018;154(12):1417-23. DOI: https://doi.org/10.1001/jamadermatol.2018.3631

Chokshi A, Demory Beckler M, Laloo A, Kesselman MM. Paradoxical Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor-Induced Psoriasis: A Systematic Review of Pathogenesis, Clinical Presentation, and Treatment. Cureus. 2023;15(8):e42791. DOI: https://doi.org/10.7759/cureus.42791

Fargnoli MC, De Simone C, Gisondi P, Calzavara-Pinton P. Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature. Dermatol Ther (Heidelb). 2023;13:2527-4. DOI: https://doi.org/10.1007/s13555-023-01024-9

Segaert S, Calzavara-Pinton P, de la Cueva P, Jalili A, Lons Danic D, Pink AE, et al. Long-term topical management of psoriasis: the road ahead. J Dermatolog Treat. 2022;33(1):111-20. DOI: https://doi.org/10.1080/09546634.2020.1729335

Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, et al. Topical treatments for scalp psoriasis. Cochrane Database Syst Rev. 2016;2(2):CD009687. DOI: https://doi.org/10.1002/14651858.CD009687.pub2